Vir Biotechnology, Inc.
About Vir Biotechnology, Inc.
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $68.6M
- Net income
- -$438.0M
- Total assets
- $1.0B
- Market cap
- $1.5B
- Gross margin
- 100.0%
- Operating margin
- -699.2%
- Net margin
- -638.9%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $68.6M
- Cost of revenue
- $26.0K
- Gross profit
- $68.5M
- Operating expenses
- $547.9M
- Operating income
- -$479.3M
- Income tax
- $217.0K
- Net income
- -$438.0M
- EPS (basic)
- $-3.16
- EPS (diluted)
- $-3.16
Balance sheet
- Total assets
- $1.0B
- Current assets
- $514.1M
- Total liabilities
- $237.5M
- Current liabilities
- $92.8M
- Shareholders’ equity
- $765.3M
Cash flow
- Operating cash flow
- -$391.8M
- Investing cash flow
- $310.4M
- Financing cash flow
- $3.8M
- Net cash flow
- -$77.6M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $1.5B
- EPS (diluted)
- $-3.16
- Dividend yield
- 1.18%
- Shares outstanding
- 172.6M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 11, 2019
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $438.0M in FY2025.
- Revenue declined 10% from FY2020 to FY2025.
- Gross margin of 100.0%, net margin -638.9%.
- Trading 24% below its 52-week high.
- Pays a dividend yielding about 1.18% annually.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Vir Biotechnology, Inc..
Write a review
News about Vir Biotechnology, Inc.
News & sentiment via Polygon.io
